1. Home
  2. AZN

as of 10-05-2026 3:38pm EST

$156.63
$1.07
-0.68%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Founded: 1992 Country:
United Kingdom
United Kingdom
Employees: N/A City: N/A
Market Cap: 250.7B IPO Year: 1995
Target Price: $212.17 AVG Volume (30 days): 2.7M
Analyst Decision: Strong Buy Number of Analysts: 11
Dividend Yield:
2.06%
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $80.48 - $212.71 Next Earning Date: 10-30-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 7.55% Revenue Growth (next year): 6.07%
P/E Ratio: 31.91 Index: N/A
Free Cash Flow: N/A FCF Growth: -4.54%

AI-Powered AZN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Precision: 29.17%
29.17%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of AstraZeneca PLC (AZN)

Sharma Mani

See Remarks

Buy
AZN Aug 8, 2026

Avg Cost/Share

$160.57

Shares

20

Total Value

$3,248.81

Owned After

19,287.699

SEC Form 4

Share on Social Networks: